HomeNewsIndiaCoronavirus impact | Uncertain if any business will be back to normal by Q2 of this fiscal: Harsh Pati Singhania

Coronavirus impact | Uncertain if any business will be back to normal by Q2 of this fiscal: Harsh Pati Singhania

While the recovery rate would vary from industry to industry, he said the service sector would take longer time to bounce back from the COVID-19 impact.

April 21, 2020 / 14:46 IST
Story continues below Advertisement

For any business, return to normalcy by the second quarter of this fiscal seems uncertain as a lot will depend on how quickly the consumers recover from the overall impact of the coronavirus outbreak and the lockdown, according to JK Organisation Director Harsh Pati Singhania.

While the recovery rate would vary from industry to industry, he said the service sector would take longer time to bounce back from the COVID-19 impact.

Story continues below Advertisement

"It is quite clear that if you look at Q1 of FY21 there would certainly be an impact... Q2 may also be affected as some businesses would have a deeper or continued impact and some businesses may see a quicker recovery. But I do not know whether any business will be back to almost normal in Q2,” Singhania told PTI.

When asked if the entire first half of the fiscal would be affected, he said: "Yes, because there would be a gradual opening of the economy.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show